Stifel Financial Corp Sells 5,083 Shares of Boston Scientific Co. (NYSE:BSX)

Stifel Financial Corp trimmed its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,003,198 shares of the medical equipment provider's stock after selling 5,083 shares during the period. Stifel Financial Corp owned approximately 0.14% of Boston Scientific worth $178,926,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Mechanics Bank Trust Department bought a new stake in shares of Boston Scientific during the 4th quarter worth $415,000. Highland Capital Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $4,887,000. Covenant Asset Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $3,405,000. Brookstone Capital Management lifted its stake in Boston Scientific by 23.7% in the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after purchasing an additional 20,307 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. lifted its stake in Boston Scientific by 31.7% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock worth $1,744,000 after purchasing an additional 4,702 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Barclays upped their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday. UBS Group increased their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, Needham & Company LLC upped their price objective on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus price target of $114.52.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,009 shares of company stock worth $14,407,381 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.82 during midday trading on Friday, hitting $101.96. 5,412,952 shares of the stock traded hands, compared to its average volume of 6,357,247. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a one year low of $70.97 and a one year high of $107.17. The firm has a market capitalization of $150.81 billion, a P/E ratio of 81.57, a PEG ratio of 2.79 and a beta of 0.73. The firm has a 50-day moving average of $98.68 and a two-hundred day moving average of $94.92.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. On average, equities analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.